June 11, 2018 / 8:22 PM / 4 months ago

BRIEF-Regenxbio Receives $100 Mln Accelerated License Payment

June 11 (Reuters) - Regenxbio Inc:

* REGENXBIO RECEIVES $100 MILLION ACCELERATED LICENSE PAYMENT DUE TO ACQUISITION OF AVEXIS BY NOVARTIS

* REGENXBIO - ACCELERATED LICENSE PAYMENT CONSISTED OF $60 MILLION IN ANNUAL FEES AND A COMMERCIAL MILESTONE FEE OF $40 MILLION

* REGENXBIO INC - NOVARTIS NOW HOLDS EXCLUSIVE RIGHTS TO NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA

* REGENXBIO INC - REGENXBIO REMAINS ELIGIBLE TO RECEIVE A POTENTIAL COMMERCIAL MILESTONE FEE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below